Salt of halogen-substituted heterocyclic compound

A halogen atom, cyclopropane carboxylic acid technology, applied in the direction of drug combination, organic chemistry, digestive system, etc., can solve the problem of undisclosed compounds and so on

Active Publication Date: 2017-02-22
UBE IND LTD
View PDF27 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] On the other hand, Patent Documents 2 to 23, Non-Patent Documents 5, 7, 8 and 16 disclose ([1,1'-biphenyl]-4-yl)acetic acid derivatives as compounds having LPA receptor antagonistic activity , In addition, Patent Document 17 discloses (2'-methoxy-[1,1'-biphenyl]-4-yl) acetic acid derivatives, and Patent Document 19 discloses 3-chloroisothiazole derivatives, but does not disclose Compounds of the invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Salt of halogen-substituted heterocyclic compound
  • Salt of halogen-substituted heterocyclic compound
  • Salt of halogen-substituted heterocyclic compound

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0221] (R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl]amino}thiophen-2-yl)-2'-methoxy-[1,1 Sodium '-biphenyl]-4-yl]cyclopropanecarboxylate (compound number I-2)

[0222]

[0223] (R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl]amino}thiophen-2-yl)-2 synthesized in the same manner as in Reference Example 29 '-Methoxy-[1,1'-biphenyl]-4-yl]cyclopropanecarboxylic acid 1.10g (2.00mmol) in acetonitrile (80ml) suspension solution, while stirring under ice bath, add 1N After adding 2.00 ml (2.00 mmol) of an aqueous sodium hydroxide solution, ultrapure water (6 ml) was added, and ultrasonic treatment was performed to obtain a homogeneous solution, followed by stirring at room temperature for 3 hours. A small amount of ultrapure water was further added to the reaction mixture, freeze-dried, and then heated and dried under reduced pressure to obtain 1.08 g (1.89 mmol, yield 95%) of the target compound as a white solid.

[0224] Mass spectrometry (ESI + , m / z): 570[M+1] + .

[...

Embodiment 2

[0227] (R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl]amino}thiophen-2-yl)-2'-methoxy-[1,1 Potassium '-biphenyl]-4-yl]cyclopropanecarboxylate (compound number I-4)

[0228]

[0229] (R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl]amino}thiophen-2-yl)-2 synthesized in the same manner as in Reference Example 29 '-Methoxy-[1,1'-biphenyl]-4-yl]cyclopropanecarboxylic acid 275mg (0.501mmol) in acetonitrile (20ml)-ultrapure water (1.5ml) suspension solution, while stirring 0.500 ml (0.500 mmol) of 1N aqueous potassium hydroxide solution was added to make a uniform solution, and ultrapure water (6 ml) was added thereto, followed by ultrasonic treatment. After allowing the reaction mixture to stand at room temperature for 30 minutes, a small amount of ultrapure water was added, freeze-dried, and then heated and dried under reduced pressure to obtain 235 mg (0.401 mmol, yield 80%) of the target compound as a white solid.

[0230] Mass spectrometry (ESI + , m / z): 586[M+1] + . ...

Embodiment 3

[0233] (R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl]amino}thiophen-2-yl)-2'-methoxy-[1,1 '-Biphenyl]-4-yl]cyclopropanecarboxylic acid 1 / 2 calcium (compound number I-6)

[0234]

[0235] (R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl]amino}thiophen-2-yl)-2'-methanol obtained in Example 1 Oxy-[1,1'-biphenyl]-4-yl]cyclopropanecarboxylate sodium 101mg (0.177mmol) in ultrapure water (25ml) solution, after adding 0.5M calcium acetate aqueous solution 0.180ml (0.090mmol) , stirred at room temperature for 2 days. The obtained suspension solution was filtered with a membrane filter (manufactured by Millipore Corporation), washed with ultrapure water, and then heated and dried under reduced pressure to obtain 40.4 mg (0.071 mmol, yield 40%) of the target compound as a white solid. .

[0236] Mass spectrometry (ESI + , m / z): 1133[2M+1] + .

[0237] 1 H-NMR spectrum (400MHz, DMSO-d 6 )δ: 9.42 (1H, brs), 7.41-7.25 (10H, m), 7.19-7.15 (2H, m), 7.07 (1H, dd, J=7.9, 1.3Hz), 5...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to view more

Abstract

The invention relates to a salt of halogen-substituted heterocyclic compound. Provided is a novel salt of an [alpha]-halogen-substituted thiophene compound that has powerful LPA receptor antagonistic action and that is useful as a pharmaceutical product. A salt represented by general formula (1) [In the formula: R is a hydrogen atom or a methoxy group; X is a halogen atom; A is a group selected from the group consisting of the following groups: (AA); M is an alkali metal or an alkali earth metal; and n is 1 when M is an alkali metal, and 2 when M is an alkali earth metal] (as shown in the description).

Description

technical field [0001] The present invention relates to novel salts of α-position halogen-substituted thiophene compounds useful as medicines. The salt of the α-position halogen-substituted thiophene compound of the present invention is useful for preventing and / or treating diseases caused by LPA because it has lysophosphatidic acid (LPA) receptor antagonistic activity. Background technique [0002] Lysophosphatidic acid (LPA) is a physiologically active phospholipid present in living organisms. LPA binds to specific G protein-conjugated receptors (LPA1, LPA2, LPA3, LPA4, LPA5, LPA6) to transmit signals in cells, thereby regulating cell proliferation, differentiation, survival, migration, adhesion, infiltration, and morphology form. It is also known that LPA intervenes in diseases accompanied by fibrosis in various organs. [0003] Regarding the liver, it has been reported that LPA promotes the proliferation and / or contraction of astrocytes, which play an important role i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D333/36A61K31/381A61P13/00A61P19/04A61P25/00A61P29/00A61P35/00A61P37/02A61P43/00
CPCA61K31/381C07D333/36A61P1/16A61P11/00A61P13/00A61P13/12A61P19/04A61P25/00A61P29/00A61P35/00A61P37/02A61P43/00
Inventor 岩瀬德明西田洋奥土诚伊藤雅章河野繁行的山正明牛山茂冈成荣治松永博文西川显治木村富美夫
Owner UBE IND LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap